290297-26-6 Usage
Description
Different sources of media describe the Description of 290297-26-6 differently. You can refer to the following data:
1. Netupitant, originally developed by Helsinn Healthcare and
later licensed to Eisai, Inc., was approved in the USA in October
2014 for the treatment of chemotherapy-induced nausea and emesis.
Akynzeo ? is a fixed-dose combination of the new drug
netupitant and the previously-approved 5-HT3 antagonist palonosetron.
While palonosetron obtained approval previously for treating
nausea and emesis occurring within the first 24 hours (acute
phase) after chemotherapy, netupitant provides a synergistic
effect with palonosetron, assisting in prevention of nausea
and emesis in later stages following chemotherapy (25–120 h after
chemotherapy treatment). Several clinical trials showed that
this combination of netupitant and palonosetron (Akynzeo ?), in
comparison to treatment with palonosetron treatment alone, led
to an improved percentage of patients in all phases who did not
experience any nausea and emesis after undergoing chemotherapy. Netupitant itself joins the class of selective Neurokinin-
1 (NK1) receptor antagonists which, in addition to their use for treating chemotherapy-induced nausea and emesis,
also play an important role as therapies for depression and
anxiety.
2. Netupitant is an insurmountable antagonist of the neurokinin-1 (NK1) receptor (Ki = 0.95 nM in CHO cells expressing the human recombinant receptor). It is selective for human NK1 over human NK2 and NK3 and rat NK1 (Kis = >1,500 nM) and over 50 G protein-coupled receptors, monoamine transporters, and ion channels when used in the nanomolar range. Netupitant decreases the maximal response to substance P-induced contractions in isolated guinea pig ileum with long-lasting effects. It also dose-dependently inhibits the substance P-induced scratching, biting, and licking response in mice when used at doses ranging from 1-10 mg/kg and decreases NK agonist-induced foot tapping in gerbils (ID50s = 1.5 mg/kg, i.p., or 0.5 mg/kg, oral). Formulations containing netupitant have been used in the treatment of chemotherapy-induced nausea and vomiting.
Uses
Netupitant is a potent and selective neurokinin-1 receptor (NK1) receptor antagonist. It is achiral and orally active.
Definition
ChEBI: A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2-[3,5-bis(trifluoromethyl)phenyl]-2-methylpropanoic acid with the secondary amino group of N-methyl-4-(2-methylphenyl)-6-(4-methylpiperazin-1-yl)pyridin
3-amine; an antiemetic used in combination with palonosetron hydrochloride (under the trade name Akynzeo) to treat nausea and vomiting in patients undergoing cancer chemotherapy.
Synthesis
The most likely process-scale synthesis
of netupitant begins with 6-chloronicotinic acid (185). From
185, a one-pot 1,4-Grignard addition/oxidation reaction, developed
to provide an improved route to NK1 receptor antagonists, was
employed for direct installation of the C4-o-tolyl substituent. Using
this procedure, treatment of 6-chloronicotinic acid (185) with otolyl
magnesium chloride and subsequent oxidation with Mn
(OAc)2 in THF/AcOH generated the o-tolyl nicotinic acid intermediate
187 in 51% overall yield. From this intermediate, a one-pot
amide formation could be realized in high yield by conversion of
the acid to the corresponding acyl chloride and addition of NH4OH
(95% yield). Chloride displacement with 1-methyl piperazine under
heating conditions provided intermediate 189 in 95% yield.
Employing Hoffman reaction conditions originally reported by
Senanayake,171 rearrangement of amide 189 with NBS/NaOMe/
MeOH enabled formation of carbamate 190 in quantitative yield.
Reduction of the carbamate with Red-Al provided the desired
mono-methylated amine. To access the final drug target, acylation
of the intermediate methyl amine with 2-(3,5-bis(trifluoromethyl)
phenyl)-2-methylpropanoyl chloride (191) provided the final drug
netupitant (XXII) in 81% yield. In this case, due to the cost of 193,
the acid precursor to 191, and starting materials previously
reported for generating 191/193, as well as issues with isolation
of pure intermediates on scale, a novel route to 191 and 193 was
also developed during this synthesis, beginning with the inexpensive
and readily available bromide 192. This 2-step synthesis of 193 includes Grignard
reagent formation, quenching with acetone to yield the intermediary
tertiary alcohol, and subsequent carbonylation (TfOH, H2O, CO then NaOH/H2O) to provide 2-(3,5-bis(trifluoromethyl)-phenyl)-2-
methylpropanoic acid 193. Finally, conversion of acid 193 to the
acyl chloride with oxalyl chloride in DCM provided the necessary
acyl chloride 191 in quantitative yield (86% purity).
Check Digit Verification of cas no
The CAS Registry Mumber 290297-26-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,9,0,2,9 and 7 respectively; the second part has 2 digits, 2 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 290297-26:
(8*2)+(7*9)+(6*0)+(5*2)+(4*9)+(3*7)+(2*2)+(1*6)=156
156 % 10 = 6
So 290297-26-6 is a valid CAS Registry Number.
InChI:InChI=1/C30H32F6N4O/c1-19-8-6-7-9-23(19)24-17-26(40-12-10-38(4)11-13-40)37-18-25(24)39(5)27(41)28(2,3)20-14-21(29(31,32)33)16-22(15-20)30(34,35)36/h6-9,14-18H,10-13H2,1-5H3
290297-26-6Relevant articles and documents
Method for preparing netupitant
-
, (2018/04/02)
The invention discloses a method for preparing netupitant, and belongs to the field of medicine compounds. The method includes the steps: performing condensation on 2-chloro-5-aminopyridine and formicacid; performing reduction, Boc protection and iodination; performing coupling and deprotection and then performing condensation on products and 2-(3, 5-bis-trifluoromethyl-phenyl)-2-methyl propionicacid; performing substitution on products and N-methylpiperazine to obtain the netupitant. The method has the advantages that the steps of processes for preparing the netupitant have fewer side effects, the method is high in yield and less in environmental pollution, after-treatment is simple, and the netupitant which is a product prepared by the aid of the method is high in purity and low in individual impurity content.
4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium as a neurokinin receptor modulator
-
, (2016/08/29)
Compounds and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the neurokinin (NK1) receptor, based on 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)3yridine-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium and pharmaceutically acceptable salts thereof.
SUBSTITUTED 4-PHENYL-PYRIDINES FOR TREATMENT OF NK-1 RECEPTOR RELATED DISEASES
-
, (2018/10/31)
PROBLEM TO BE SOLVED: To provide new derivatives of 4-phenyl-pyridine compounds that are effective NK1 receptor antagonists, with enhanced physicochemical and/or biological properties, and methods for producing the 4-phenyl-pyridine compounds. SOLUTION: Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the neurokinin (NKj) receptor. The compounds have the general formula (I). COPYRIGHT: (C)2015,JPOandINPIT
